Patel Karishma, Stummer Lauren, Patel Krina
Ment Health Clin. 2020 May 7;10(3):95-99. doi: 10.9740/mhc.2020.05.095. eCollection 2020 May.
Stiff-person syndrome (SPS) is a neurologic disorder characterized by muscle stiffness, rigidity, and muscle spasms, and it can increase a patient's risk for falls. It is recognized as a rare disease with limited clinical guidelines to manage the condition and its symptoms. Currently, there is even less clinical guidance for the management of common comorbid conditions in these patients. This patient case report aims to evaluate the efficacy of various medications for symptom management in a patient with SPS and comorbid psychiatric disorders, specifically bipolar I and panic disorder. Throughout the patient's course of treatment, various medications were trialed, including fluoxetine, hydroxyzine, valproic acid, propranolol, and clonazepam. Ultimately, fluoxetine, hydroxyzine, and propranolol were discontinued due to adverse drug reactions and incomplete symptom resolution. The patient's bipolar I disorder was adequately managed with valproic acid. Once the clonazepam was changed from as-needed to scheduled dosing, the patient's panic disorder and anxiety-triggered spasms were well controlled. The efficacy of benzodiazepines, specifically high doses of diazepam, in alleviating muscle spasms and anxiety in SPS has been demonstrated in the literature. Case reports including patients with SPS that are prescribed selective serotonin reuptake inhibitors provide controversial evidence as some studies report exacerbation of SPS symptoms with prolonged use. As this case report and literature review suggest, patients with SPS and comorbid panic disorder and anxiety-triggered spasms may benefit from the use of benzodiazepines. The use of other medication classes for the treatment of other comorbid psychiatric disorders in a patient with SPS is lacking evidence.
僵人综合征(SPS)是一种神经系统疾病,其特征为肌肉僵硬、强直和肌肉痉挛,会增加患者跌倒的风险。它被认为是一种罕见疾病,针对该病症及其症状的临床指南有限。目前,对于这些患者常见合并症的管理,临床指导更少。本病例报告旨在评估各种药物对一名患有SPS及合并精神障碍(特别是双相I型障碍和惊恐障碍)患者症状管理的疗效。在患者的整个治疗过程中,试用了多种药物,包括氟西汀、羟嗪、丙戊酸、普萘洛尔和氯硝西泮。最终,由于药物不良反应和症状缓解不完全,氟西汀、羟嗪和普萘洛尔被停用。患者的双相I型障碍通过丙戊酸得到了充分控制。一旦氯硝西泮从按需给药改为定时给药,患者的惊恐障碍和焦虑引发的痉挛就得到了很好的控制。文献表明,苯二氮䓬类药物,特别是高剂量地西泮,在缓解SPS患者的肌肉痉挛和焦虑方面具有疗效。包括使用选择性5-羟色胺再摄取抑制剂的SPS患者的病例报告提供了有争议的证据,因为一些研究报告长期使用会使SPS症状加重。正如本病例报告和文献综述所表明的,患有SPS及合并惊恐障碍和焦虑引发痉挛的患者可能会从使用苯二氮䓬类药物中受益。对于SPS患者使用其他药物类别治疗其他合并精神障碍缺乏证据。